• Peter Poon, Rae Frances Bell, and Phillip Good.
• Monash University (P.P.), Faculty of Medicine Nursing and Health Sciences, Clayton, Victoria, Australia; Supportive and Palliative Care Department (P.P.), Monash Health, Clayton, Victoria, Australia. Electronic address: peter.poon@monash.edu.
• J Pain Symptom Manage. 2024 Aug 1; 68 (2): e146e151e146-e151.

AbstractIn the cancer pain setting, ketamine has been typically employed as a co-analgesic for opioid refractory and neuropathic pain. One controversial topic is whether subanesthetic ketamine be considered when managing opioid refractory cancer pain. In this "Controversies in Palliative Care" article, three clinicians independently answer this question. Specifically, each clinician provides a synopsis of the key studies that inform their thought processes, share practical advice on their clinical approach, and highlight the opportunities for future research. Three independent clinicians reported a divergence of opinion regarding the usefulness of subanesthetic ketamine for managing opioid refractory cancer pain. All investigators acknowledged the lack of high-quality trials. All agreed on the need for adequately powered trials, the development of standardized methodology, and the exploration of any patient sub-populations that may benefit from ketamine for cancer related pain.Copyright © 2024 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

17 keywords...

hide…